CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for IRulya Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

IRulya Therapeutics Inc
601 Gateway Boulevard, Suite 1250
Phone: (415) 910-5717p:415 910-5717 SOUTH SAN FRANCISCO, CA  94080  United States Ticker: IRLAIRLA
Business Summary
IRulya Therapeutics, Inc., formerly Quince Therapeutics, Inc., is a clinical-stage biopharmaceutical company. It is developing a novel disease-modifying therapeutic to address the unmet medical need associated with pulmonary disorders. Its lead asset, LAM-001, a proprietary investigational inhaled dry powder formulation of rapamycin whose differentiated characteristics may permit treatment of pulmonary conditions associated with dysfunctional mammalian target of rapamycin activity. It is evaluating the use of LAM-001 as a treatment for patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and for patients with bronchiolitis obliterans syndrome post lung transplant (BOS). It also completed a Phase 2a trial, which enrolled patients with pulmonary arterial hypertension as well as patients with PH-ILD and sarcoidosis associated pulmonary hypertension (SAPH) where it achieved clinically relevant improvement across multiple endpoints, and others.
(Source: 6-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202612/31/2025YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer and Principal Executive Officer, Director BrigetteRoberts 50 10/8/2026 5/18/2026
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer JohnMilitello 53 10/8/2026 10/8/2026
Chief Operating Officer Keith R.Fandrick 47 10/8/2026 10/8/2026
4 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Erydel S.p.A. Via Antonio Meucci, 3 Bresso Italy
OrphAI Therapeutics Inc 101 College Street New Haven CT United States

Business Names
Business Name
AI Therapeutics Inc
Cortexyme Australia Pty Ltd
CORTEXYME INC
11 additional Business Names available in full report.

General Information
Number of Employees: 38 (As of 12/31/2025)
Outstanding Shares: 10,841,470 (As of 10/9/2026)
Shareholders: 28
Stock Exchange: NASD
Federal Tax Id: 901024039
Fax Number: (302) 655-5049
Email Address: info@cortexyme.com


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, November 14, 2026